Citations

Showing 10 of 108104 citations.

Human Plasma And Platelet Factor V Levels As Measured By Radioimmunoassay
Tracy, PB, Peterson, James M., Nesheim, ME, Katzmann, J A, Mann, Kenneth G.

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652216 Get It

Highly purified human Factor V was used for the development of a competitive double antibody radioimmunoassay (RIA) using 125I-human Factor V, burro anti-human Factor V antisera as the primary antibody and goat anti-burro antisera as the precipitating antibody. The standard curve allows the detection of as little as 20 ng of Factor V per ml of plasma. With this specific RIA for human Factor V, we have measured the level of Factor V in the plasma and platelets of normal individuals. The normal level of Factor V in plasma ranges from 4 to 14 μg per ml, with the average value equal to 7.0 ± 2.0 μg/ml (n = 64; 33 females; 31 males; 22 to 61 years of age). There appeared to be no correlation between antigen levels and age or sex. Factor V clotting assays were consistent with the RIA data for any given plasma preparation providing freshly drawn plasma was used in the bioassay. The bioassay data were quantitated based upon the specific activity of purified plasma Factor V; 1.7 units of Factor V equals 1 μg of protein. Plasma Factor V antigen levels were not affected by lyophilization of the plasma, prolonged storage of the plasma at -20°C or intentional conversion of the plasma to serum. The levels of Factor V present in washed human platelets were also determined using the RIA. Assay of washed platelets lysed in 0.2% Triton X-100 indicated that 0.6 to 0.85 μg of Factor V was present per 2.5 × 108 platelets (4400 to 6200 molecules of Factor V per platelet). This result is in marked contrast to our observations for the bovine system, where we found that bovine platelets possess approximately 400 to 800 molecules of Factor V per platelet, and plasma Factor V levels range from 30 to 50 μg per ml. In the bovine system, the platelets possess approximately 1% of the total Factor V present, while in human blood, the platelets possess as much as 10 to 15% of the total Factor V present.
Isolation And Properties Of Intermediates Involved In Thrombin-Catalyzed Conversion Of Bovine Factor V To Factor Va
Nesheim, Michael E., Mann, K G

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652212 Get It

Bovine Factor V was incubated briefly with bovine β- thrombin, causing partial conversion to Factor Va. QAE- cellulose chromatography in Ca++ of the partially activated material yielded 3 fractions. Electrophoresis in DodSO4 indicated primarily starting material (Mr=330,000) in the first fraction; two peptides of Mr=150,000 and 200,000 in the second; and two peptides of Mr=200,000 and 90,000 in the third. The first of these latter fractions was active only after further incubation with thrombin, while the other was active without further thrombin catalyzed activation. After thrombin treatment both fractions had specific activities equal to that of fully activated, unfractionated Factor V. Incubation of either of these fractions with EDTA caused complete loss of activity and allowed isolation of the constituent polypeptides by further chromatography on QAE- cellulose in EDTA. The NH2-termini of the 150,000 and 90.000 apparent Mr peptides had sequences identical to that of Factor V. The 200,000 apparent Mr peptides of the two fractions obtained by chromatography in Ca++ had NH2- terminal sequences identical to each other but different from that of Factor V. The summed amino acid compositions of the Mr=200,000 and Mr=150,000 were equivalent to that of Factor V. Electrophoretic analysis indicated that thrombin converts the Mr=150,000 peptide to endproducts of Mr=90,000 and 71,000, and the Mr=200,000 peptide to endproducts of 83.000 and 31,000 apparent Mr. Recalcification of the individual isolated intermediates, followed by incubation with thrombin did not yield cofactor activity. Recombina- ion of the recalcified intermediates followed by incubation with thrombin, however, generated samples with activities approaching that of unfractionated, activated Factor V. These data indicate that the intermediates of Mr=150,000 and Mr=200,000 arise by a single cleavage of Factor V, and that Factor Va comprises peptides derived from both of these intermediates.
Endothelial Permeability And C-14- And I-131-Cholesterol Uptake On Aortocoronary Femoral Vein Bypass Grafts In Dogs
Dewanjee, Mrinal K., Shapira, Nadiv, Kaye, Michael P., Tago, M, Fuster, Valentı́n

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652171 Get It

Eighteen dogs underwent aortocoronary femoral vein bypass graft surgery. All dogs were injected with 300 μCi of I-131-iodocholesterol and 100 μCi of C-14-cholesterol and sacrificed 24 hours postoperatively: group I dogs, 1 day; group II dogs, 3 days; group III dogs, 7 days; and group IV dogs, 1 year after surgery respectively. Radioactivity in blood, grafted femoral vein (GFV), control femoral vein (CFV), femoral artery, aorta and vena cava were determined with Beckman gamma and beta counters. Results indicate a sixfold increase in permeability as assessed by uptake of cholesterol in grafted vein with respect to control vein in the 1-day period postsurgery.The cholesterol uptake in GFV (p<.01) decreases to half of this value seven days after surgery. Scanning electron microscopy demonstrates patchy endothelial cell loss from GFV and slow re-endothelialization which decreases cholesterol uptake.Vein graft permeability as assessed by cholesterol uptake thus provides a sensitive marker of graft de- endothelialization. This information is now permitting us to better understand the platelet-arterial wall interaction and of the role of platelet inhibiting drugs at different stages after aortocoronary bypass surgery.
Platelet Factor 4 (PF4) And β-Thromboglobulin (BTG) In Atherosclerosis And Diabetes Mellitus
Kazmier, F J, Bowie, Ejw, O’Fallon, W. Michael, Palumbo, P J

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652031 Get It

Distinguishing between in vitro and in vivo release of platelet specific proteins has led to problems in interpretation of clinical studies with PF4, and with BTG.As part of a prospective study of peripheral occlusive arterial disease in diabetes mellitus PF4 and BTG were measured together by specific radioimmunoassay in four groups of subjects age 50-70 years. Groups included (1) 106 normal subjects (NC); (2) 126 with clinical and objective evidence (transcutaneous doppler ultrasound and treadmill exercise) of peripheral arterial occlusive disease (ASO); (3) 244 with diabetes mellitus without ASO and (4) 101 with both diabetes mellitus and ASO.PF4 did not distinguish among the four groups: NC vs ASO p=. 18, NC vs DM p=.52, NC vs DM+ASO p=.73, NC vs all diabetics p=.61, and NC vs all ASO p=.46. However, BTG did distinguish the groups with vascular disease from NC: NC vs ASO p=.02, NC vs DM+ASO p<.001, NC vs DM p=.32, DM vs DM+ASO p<.01, all ASO vs all nonASO p<.001.Normal range for PF4 is 0-13 ng/ml with a median of 3.0 ng/ml, a mean of 3.0 ng/ml, and SD 1.97. Normal range for BTG is 14-46 ng/ml with a median of 26 ng/ml, a mean of 27.2 ng/ml, and SD 10.3. When PF4 and BTG are correlated (all groups included) r=.41 p<.001.PF4 and BTG levels should be performed together. When done together low PF4 levels support the absence of in vitro platelet release due to sample collection and handling. BTG levels are significantly increased in subjects with peripheral arterial disease, supporting the active role of platelets in thrombotic occlusive arterial disease.
The Influence Of Physiological Parameters On The Plasma Concentration Of β-Thromboglobulin (β-TG) And Platelet Factor 4 (PF-4) In Normal Healthy Subjects
Duncan, Alison, Didisheim, Paul

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652030 Get It

The variability of normal ranges in different laboratories and the occurrence of occasional elevated values of β-TG and PF-4 in normal subjects are well established. We examined the influence of factors such as age, sex, smoking, exercise, oral contraceptives and day-to-day variation in 148 healthy subjects. The β-TG and PF-4 assays were performed by commercial RIA’s modified by utilizing an EDTA- PGE1 -theophylline mixture as anticoagulant.The statistical method used to compare our groups was a student t-test after log transformation of the data. Our baseline control group (N=63) were non smokers and not taking oral contraceptives (O/C) or any medications. There was no difference between sexes or a significant change with increasing age, although the mean β-TG and PF-4 does increase in cohosts of 20 years. [<30 years (21.65±8.35)(SD), 30-50 years (24.32±10.94) >50 years (27.88±14.3)-β-TG data].Women on O/C were significantly different from those not on O/C for β-TG [35.06±22.45 (O/C) and 23.67±9.38 (N)] but not for PF-4 values [3.79±1.77 (O/C) and 3.91±1.63 (N)].Strenuous exercise was the parameter that influenced both β-TG and PF-4 significantly, showing an elevated value after exercise for both β-TG [81.9±31.4 v 26.73±10.91] and PF-4 [7.08±1.71 v 3.73±1.91].Day-to-day variations in β-TG and PF-4 were examined in 10 subjects for 7-10 days. The coefficient of variation (CV) amongst these subjects was 21-51%. In athletes day-today variation was the same unless a change in pattern of exercise occurred [CV-49-132%].Our results confirm that parameters such as above do influence normal values and should be taken into consideration in establishing a normal range.It also indicates the β-TG is a more sensitive parameter for delineating differences in physiological parameters in normal subjects than PF-4, and this may be applicable to clinical studies.
The Coagulant Active Phospholipid(Pl) Content Of Prothrombin Complex Concentrates(Pcc) Is A Critical Determinant Of Their In Vivo Thrombogenicity
Giles, Alan R., Nesheim, ME, Tracy, Paula B., Hoogendoorn, H, Mann, K G

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1651978 Get It

It has generally been assumed that the thrombogenicity of PCC relates to their invariable contamination by activated products of their component clotting factors. In earlier studies we demonstrated a lack of correlation between the activated clotting factor content ᶓ in vivo thrombogenicity of some PCC. In contrast, in vitro measurement of coagulant active PL content appeared to be a more reliable determinant of subsequent in vivo activity. In recent studies we have confirmed the presence of PL of known coagulant activity in PCC ᶓ studied its activity both in vitro ᶓ in vivo after its extraction from the parent PCC.PCCs were obtained from various agencies or prepared in our laboratory to a standard protocol either from fresh frozen plasma or plasma obtained from outdated platelet concentrates. Each was assayed for Xa (S-2222) ᶓ PL (thrombin generation assay with DAPA) ᶓ an index of thrombogenicity in vivo determined in a stasis model in rabbits. There was a significant correlation between the latter ᶓ PL (r=0.8727 p<0.01) but not Xa. Thin layer chromatography of an ethanol ether extract of the most thrombogenic PCC showed the presence of PL known to be coagulant active including Phospho- tidylserine ᶓ -choline. This extract retained full PL replacing activity in the DAPA assay in vitro but was non- thrombogenic in vivo. When, however, a highly purified preparation of Xa was added, in the same relative proportions as in the parent PCC, thrombogenicity in vivo was restored.It is concluded that the content of coagulant active PL is a critical determinant of the potential thrombogenicity of PCC in vivo. It appears to act in concert with Xa ᶓ conceivably, other serine proteases perhaps by protecting them from inactivation by AT III. This may explain why relatively “non-activated” PCCs may still be associated with thromboembolic complications.
The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions
Bagaria, Sanjay P. , Neville, Matthew R., Gray, Richard J. , Gabriel, Emmanuel , Ashman, Jonathan B. , Attia, Steven , Wasif, Nabil , Neville, Matthew, Bagaria, Sanjay P , Gabriel, Emmanuel

Mayo Clinic

Sarcoma | July 24, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-10

10.1155/2018/3056562 | PMID 30140165 Get It

Background. We sought to study the association between RPS case volume and outcomes. Although a relationship has been demonstrated between case volume and patient outcomes in some cancers, such a relationship has not been established for retroperitoneal sarcomas (RPSs). Study Design. The National Cancer Database (NCDB) was queried for patients undergoing treatment for primary RPS diagnosed between 2004 and 2013. Mean annual patient volume for RPS resection was calculated for all hospitals and divided into low volume (<5 cases/year), medium volume (5–10 cases/year), and high volume (>10 cases/year). Risk-adjusted regression analyses were performed to identify predictors of 30-day surgical mortality, R0 margin status, and overall survival (OS). Results. Our study population consisted of 5,407 patients with a median age of 61 years, of whom 47% were male and 3,803 (70%) underwent surgical resection. Absolute 30-day surgical mortality and R0 margin rate following surgery for low-, medium-, and high-volume institutions were 2.4%, 1.3%, and 0.5% (p=0.027) and 68%, 65%, and 82%, (p<0.001), respectively. Five-year overall survival rates for low, medium, and high-volume institutions were 56%, 57%, and 66%, respectively (p<0.001). Patients treated at low-volume institutions had a significantly higher risk of 30-day mortality (adjusted OR = 4.66, 95% CI 2.26–9.63) and long-term mortality (adjusted HR = 1.56, 95% CI 1.16–2.11) compared to high-volume institutions. Conclusion. We demonstrate the existence of a hospital sarcoma service line volume-oncologic outcome relationship for RPS at the national level and provide benchmark data for cancer care delivery systems and policy makers.
Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia
Hammond, William A. , Advani, Pooja , Dyke, Daniel Van, Foran, James M. , Jiang, Liuyan , Van Dyke, Daniel, Foran, James M , Ketterling, Rhett P. , Dyke, Daniel L. Van

Mayo Clinic

Case Reports in Hematology | July 24, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/7456378 | PMID 30140473 Get It

Updated WHO criteria define mixed phenotype acute leukemia (MPAL) with more stringent diagnostic criteria than the formerly described entity biphenotypic acute leukemia (BAL). The changes in diagnostic criteria influence management by assigning weight to aberrantly expressed markers and minimizing expression of myeloid markers other than myeloperoxidase (MPO), potentially foregoing consolidative allogeneic transplant for an otherwise “favorable” lymphoid phenotypic leukemia. We present a case of MPO-negative, myeloid antigen-positive acute lymphoblastic leukemia who progressed with refractory phenotypic acute myeloid leukemia while receiving lymphoid-directed therapy and discuss concerns raised by the adoption of the new, more stringent diagnostic criteria for BAL.
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)
O’Neill, Anne, Gradishar, William J. , Hobday, Timothy J. , Goldstein, Lori J. , Bloom, Stuart H. , Brufsky, Adam , Sparano, Joseph A. , Le‐Lindqwister, Nguyet, Hendricks, Carolyn B., Northfelt, Donald W. , Dang, Chau T. , O'Neill, Anne, Gradishar, William, Mayer, Ingrid A. , Bloom, Stuart , Brufsky, Adam M., Le-Lindqwister, Nguyet Anh, Brufsky, Adam M , Sparano, Joseph A , Miller, Kathy D. , Tevaarwerk, Amyé , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2018 | Volume: 36 | Issue: 25 | Pages: 2621-2629

10.1200/jco.2018.79.2028 | PMID 30040523 Get It

PurposeBevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2–negative disease.Patients and MethodsPatients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C). Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule. Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The primary end point was invasive disease–free survival (IDFS).ResultsFour thousand nine hundred ninety-four patients were enrolled. Median age was 52 years; 64% of patients were estrogen receptor positive, 27% were lymph node negative, and 78% received dose-dense AC. Chemotherapy-associated adverse events including myelosuppression and neuropathy were similar across all arms. Grade ≥ 3 hypertension was more common in bevacizumab-treated patients, but thrombosis, proteinuria, and hemorrhage were not. The cumulative incidence of clinical congestive heart failure at 15 months was 1.0%, 1.9%, and 3.0% in arms A, B, and C, respectively. Bevacizumab exposure was less than anticipated, with approximately 24% of patients in arm B and approximately 55% of patients in arm C discontinuing bevacizumab before completing planned therapy. Five-year IDFS was 77% (95% CI, 71% to 81%) in arm A, 76% (95% CI, 72% to 80%) in arm B, and 80% (95% CI, 77% to 83%) in arm C.ConclusionIncorporation of bevacizumab into sequential anthracycline- and taxane-containing adjuvant therapy does not improve IDFS or overall survival in patients with high-risk human epidermal growth factor receptor 2–negative breast cancer. Longer duration bevacizumab therapy is unlikely to be feasible given the high rate of early discontinuation.
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Liu, Deli , Takhar, Mandeep, Alshalalfa, Mohammed , Erho, Nicholas , Shoag, Jonathan E. , Jenkins, Robert B. , Karnes, R. Jeffrey , Ross, Ashley E. , Schaeffer, Edward M. , Rubin, Mark A. , Klein, Eric A. , Tomlins, Scott A. , Spratt, Daniel E. , Spratt, Daniel E , Klein, Eric A , Trock, Bruce J , Den, Robert B. , Davicioni, Elai , Sboner, Andrea , Barbieri, Christopher , Rubin, Mark A

Mayo Clinic

JCO Precision Oncology | July 24, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-13

10.1200/po.18.00036 | PMID 30761387 Get It

Purpose Molecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations. One of these core subtypes, SPOP (speckle-type POZ protein) mutant prostate cancer, has previously only been identifiable via DNA sequencing, which has made the impact on prognosis and routinely used risk stratification parameters unclear. Methods We have developed a novel gene expression signature, classifier (Subclass Predictor Based on Transcriptional Data), and decision tree to predict the SPOP mutant subclass from RNA gene expression data and classify common prostate cancer molecular subtypes. We then validated and further interrogated the association of prostate cancer molecular subtypes with pathologic and clinical outcomes in retrospective and prospective cohorts of 8,158 patients. Results The subclass predictor based on transcriptional data model showed high sensitivity and specificity in multiple cohorts across both RNA sequencing and microarray gene expression platforms. We predicted approximately 8% to 9% of cases to be SPOP mutant from both retrospective and prospective cohorts. We found that the SPOP mutant subclass was associated with lower frequency of positive margins, extraprostatic extension, and seminal vesicle invasion at prostatectomy; however, SPOP mutant cancers were associated with higher pretreatment serum prostate-specific antigen (PSA). The association between SPOP mutant status and higher PSA level was validated in three independent cohorts. Despite high pretreatment PSA, the SPOP mutant subtype was associated with a favorable prognosis with improved metastasis-free survival, particularly in patients with high-risk preoperative PSA levels. Conclusion Using a novel gene expression model and a decision tree algorithm to define prostate cancer molecular subclasses, we found that the SPOP mutant subclass is associated with higher preoperative PSA, less adverse pathologic features, and favorable prognosis. These findings suggest a paradigm in which the interpretation of common risk stratification parameters, particularly PSA, may be influenced by the underlying molecular subtype of prostate cancer.